Principal Financial Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-16,303
| Closed | -$256K | – | 2501 |
|
|
2024
Q1 | $256K | Sell |
16,303
-865
| -5% | -$13.3K | ﹤0.01% | 2122 |
|
|
2023
Q4 | $277K | Sell |
17,168
-1,098
| -6% | -$14K | ﹤0.01% | 2083 |
|
|
2023
Q3 | $232K | Buy |
18,266
+1,699
| +10% | +$23.4K | ﹤0.01% | 2122 |
|
|
2023
Q2 | $233K | Buy |
16,567
+983
| +6% | +$14.1K | ﹤0.01% | 2140 |
|
|
2023
Q1 | $241K | Buy |
15,584
+1,540
| +11% | +$25.7K | ﹤0.01% | 2138 |
|
|
2022
Q4 | $230K | Buy |
14,044
+2,076
| +17% | +$33.8K | ﹤0.01% | 2160 |
|
|
2022
Q3 | $221K | Buy |
11,968
+1,718
| +17% | +$27K | ﹤0.01% | 2182 |
|
|
2022
Q2 | $134K | Buy |
+10,250
| New | +$113K | ﹤0.01% | 2356 |
|
|
2021
Q4 | – | Sell |
-19,056
| Closed | -$648K | – | 2666 |
|
|
2021
Q3 | $648K | Sell |
19,056
-297
| -2% | -$9.48K | ﹤0.01% | 2103 |
|
|
2021
Q2 | $708K | Sell |
19,353
-1,524
| -7% | -$59K | ﹤0.01% | 2129 |
|
|
2021
Q1 | $937K | Sell |
20,877
-438
| -2% | -$20.4K | ﹤0.01% | 2005 |
|
|
2020
Q4 | $1.22M | Buy |
21,315
+4,820
| +29% | +$286K | ﹤0.01% | 1901 |
|
|
2020
Q3 | $846K | Sell |
16,495
-740
| -4% | -$36.3K | ﹤0.01% | 1905 |
|
|
2020
Q2 | $1.03M | Buy |
17,235
+9,667
| +128% | +$517K | ﹤0.01% | 1824 |
|
|
2020
Q1 | $312K | Buy |
7,568
+411
| +6% | +$22.8K | ﹤0.01% | 1957 |
|
|
2019
Q4 | $445K | Buy |
+7,157
| New | +$340K | ﹤0.01% | 1971 |
|
Other funds holding DCPH
Principal Financial Group's DCPH Position: Q2 2024 in Review
Principal Financial Group sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 16,303 shares — an estimated $256K sold.
Principal Financial Group first reported a position in DCPH in Q4 2019 and held it in 16 quarters. The position peaked at $1.22M in Q4 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Principal Financial Group reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Principal Financial Group sold 16,303 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $256K.
- Principal Financial Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 16 quarters.
- Principal Financial Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.